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Hypothesis: The 2-[18F]-fluoro-2-deoxy-D-glucose positron emis-
sion tomography is an imaging tool for assessing clinical tumor,
node, metastasis in non-small cell lung cancer (NSCLC). Primary
tumor standardized uptake value (SUV) has been studied as a
potential prognostic factor for survival. However, the sample sizes
are limited leading to conduct a meta-analysis to improve the
precision in estimating its effect.
Methods: We performed a systematic literature search. For each
publication, we extracted an estimate of the hazard ratio (HR) for
comparing patients with a low and a high SUV and we aggregated
the individual HRs into a combined HR, using a random-effects
model.
Results:We found 13 eligible studies dedicated to NSCLC. Most of
them included patients with stages I to III/IV and used a SUV
assessment corrected for body weight. Number of patients ranged
from 38 to 315 (total: 1474); 11 studies identified a high SUV as a
poor prognostic factor for survival although two studies found no
significant correlation between SUV and survival. SUV measure-
ment and SUV threshold for defining high SUV were study depen-
dent, eight studies looked for a so-called best cutoff (maximizing the
logrank test statistic) without adjusting the p value for multiplicity.
Overall, the combined HR for the 13 reports was 2.27 (95%
confidence interval [CI]: 1.70–3.02); excluding the studies propos-
ing a “best” cutoff, it was 2.08 (95% CI: 1.431–3.04).
Conclusion: Our meta-analysis suggests that the primary tumor
SUV measurement has a prognostic value in NSCLC; these results
should be confirmed in a meta-analysis on individual patients’ data.
Key Words: SUV, Meta-analysis, Non-small cell lung cancer, PET
scan.
(J Thorac Oncol. 2008;3: 6–12)
With the exception of stage and performance status, noprognostic factors have been definitively established in
lung cancer.1,2 Clinical features including gender, age, weight
loss, and serum markers, such as lactate dehydrogenase,
neuron-specific enolase, cytokeratin fragment 21-1 levels, or
leukocytes or neutrophils counts, have been studied but are
not sufficiently accurate for individual patient manage-
ment.2,3 More accurate markers would be helpful to stratify
patients for therapy and predict outcomes.
Cancer stage is currently the most important prognostic
factor for survival, also having implications in the therapeutic
strategy. The last, and 6th edition of the TNM Classification
of Malignant Tumors, mainly based on surgical patients, was
published in 1997.4 This staging system relied on conven-
tional imaging (cases collected from 1975), but during the
last decade, positron emission tomography (PET) with the
glucose analogue 2-[18F]-fluoro-2-deoxy-D-glucose (18F-
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FDG) has emerged as an useful tool for several malignancies.
For lung cancer, two meta-analyses5,6 have established the
superiority of 18F-FDG-PET over computed tomography
(CT) and other imaging modalities for the diagnosis and
staging of lung cancer.
Other retrospective studies have explored the survival
prognostic significance of the standardized uptake value
(SUV) value, a semiquantitative simplified measurement of
tissue deoxyglucose metabolic rate, but most of these reports
only include a small number of patients. Based on these
considerations and in the context of the International Asso-
ciation for the Study of Lung Cancer (IASLC) Staging
Project proposals for the forthcoming, 7th edition of the TNM
Classification for Malignant Tumors, we performed a sys-
tematic review of the literature on 18F-FDG-PET scan and
survival and a meta-analysis of the data to determine the
prognostic value of primary tumor SUV in patients with lung
cancer.
MATERIALS AND METHODS
To be eligible for the systematic review, a study had to
fulfill the following criteria: limited to lung cancer (any stage
or any histology), 18F-FDG-PET studies performed on a
dedicated device (excluding gamma-camera), to assess the
relationship between pretherapeutic SUV and survival at least
in univariate analysis, and to have been published as a peer
reviewed article in the English, Dutch, or French language.
Abstracts were excluded as it cannot be expected to find
enough details to assess methodology or survival information
to perform meta-analysis. Reports using all modalities of care
were included.
Studies were identified by an electronic search on
Medline databank using the following keywords: “lung or
lung cancer or lung carcinoma or nonsmall cell or non small
cell or NSCLC or small cell or SCLC or lung neoplasms” and
“positron emission tomography or PET or PET imaging
tomography” and “FDG-F18or FDG or 18F-fluorodeoxyglu-
cose or 18F-FDG” and “SUV or standardized uptake value or
uptake value” and “prognosis or prognostic factor or out-
come,” and “survival.” The references reported in all the
identified studies were used to complete this search which
ended in June 2006. The final list of articles eligible for the
review was analyzed to identify articles in which there might
be overlap in the cohorts of patients used.
Eleven physicians and one biostatistician reviewed all
the publications to assess their methodological quality, to
determine their eligibility for inclusion in the quantitative
meta-analysis and to extract the most important information
determining the clinical and PET characteristics. A method-
ological quality scale was designed for the purpose of this
study using the variables available in the publications. This
score assessed the clinical and PET reports. The clinical
report included the distribution of the expected “prognostic
factors” (age, gender, performance status, stage, histology,
and weight loss), tumor stage description, staging character-
istics (definition of the size of a pathologic mediastinal
adenopathy, systematic use of a CT thorax for lung staging,
systematic metastatic work-up, systematic use of a CT or
magnetic resonance imaging of brain, histologic confirmation
of metastatic mediastinal adenopathy, and if the analysis of
the relationship between SUV was performed without knowl-
edge of survival results and conversely [double blind]), de-
scription of the results of survival analysis (number of pa-
tients, number of deaths, follow-up duration, number of
patients lost to follow-up, univariate and multivariate analy-
ses, description of statistical tests, survival definition, SUV
cutoff definition). The PET report included patients char-
acteristics (weight/height, glycaemia, histologic subtype),
18F-FDG-PET acquisition protocol characteristics (injected
dose of 18F-FDG, delay between injection and data acquisi-
tion, fasting duration), and technical parameters (investiga-
tion area, delay between CT thorax and PET acquisition,
SUV formula, type of PET engine, duration of emission time,
duration of transmission time, attenuation and reconstruction
parameters, type of SUV). The clinical and PET reports were
respectively scored on 44 and 40 points. A value between 0
and 2 was attributed to each item. When an item was not
applicable to a particular study, it was ruled out. The scores
were expressed in percentage of the maximal theoretical
value that can be obtained.
The following methodology, as we have already used in
previous meta-analyses,7,8 was applied for aggregating the
estimated effects of the 18F-FDG-PET SUV on survival. We
measured the impact of SUV on survival by hazard ratio (HR)
between the survival distributions of two groups. For each
trial, this HR was estimated by a method depending on the
results provided in the publication. The most accurate method
consisted to retrieve the HR estimate and its variance from
the reported results, or to calculate them directly using pa-
rameters given by the authors for the univariate analysis: the
O-E statistic (difference between numbers of observed and
expected events), the confidence interval (CI) for the HR, the
logrank statistic, or its p value. If not available, we looked for
the total number of events, the number of patients at risk in
each group, and the logrank statistic or its p value, allowing
calculation of an approximation of the HR estimate. Finally,
if the only exploitable data were in the form of graphical
representations of the survival distributions, we extracted
from them survival rates at some specified times to recon-
struct the HR estimate and its variance, with the assumption
that the rate of patients censored was constant during the
study follow-up.9 If authors report survival of three or more
groups (for example, using several cutoff values for SUV),
we pooled the results making a comparison between two
groups feasible. The individual HR point estimates were
combined after acceptation of the null hypothesis of the
homogeneity of the treatment effect across the various trials,
using the Peto method10 to obtain a global HR estimate of the
treatment effect. By convention, a HR 1 implied a survival
benefit for lower primary tumor SUV. The HR was calculated
using a fixed-effects method. In case of significant test for
heterogeneity (p  0.10), a random-effects method was
applied. This impact of SUV on survival was considered as
statistically significant if the 95% CI for the overall HR did
not overlap 1. All reported p values were two-tailed.
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RESULTS
Sixteen studies, published between 1998 and 2006 were
potentially eligible for this review.11–26 Three studies in-
cluded similar cohorts of patients15–17 and we took into
account only the most complete one. One study was not
assessable for meta-analysis because no quantitative thresh-
old was evaluated (in this study a 18F-FDG-PET scan was
interpreted as negative if the tumor uptake of 18F-FDG was
less than or equal to mediastinal uptake).12 In two other
studies, patients without definite diagnosis of cancer were
reported in the analysis without separated results between
cancer patients and the others.13,14 To reduce the risk of error
by including patients without cancer, we performed two
meta-analyses one with and one without these two studies.
The principal characteristics of the 13 studies eligible
for the meta-analysis are described in Table 1. The majority
of the 1474 patients presented with nonmetastatic non-small
cell lung cancer (NSCLC); there were only two small cell
lung cancers and one carcinoid tumor.20 Patients were gen-
erally staged according to the 1997 edition of the TNM
Classification of Malignant Tumors. According to the thresh-
old defined by the authors, high SUV was associated with
poor prognosis in 11 studies whereas in two, the prognostic
role of SUV for survival remained undetermined. The main
SUV characteristics reported in the publication are described
in Table 2. SUVmax was used in eight studies, normalized by
body weight in seven (Appendix 1) and by lean body mass in
one (Appendix 2). In three studies, the authors used SUVmean
normalized by body weight, with different percentages for
defining the isocontours of the volume of interest around the
tumor. In one study, SUVmax and SUVmean normalized by
body weight and by lean body mass were studied but only the
SUVmean normalized by body weight was used for the sur-
vival analysis. The choice of the SUV threshold between
patients with high survival and low survival was based on
eight cases on a so-called best cutoff, meaning that the
authors chose as SUV threshold the value maximizing the
logrank test statistic among several survival comparisons.
This method is known to lead to a high risk of false-positive
result especially if no adjustment of p values for multiplicity
is done. In the other publications, the threshold was arbitrarily
chosen (n  1), based on the median (n  3) SUV values or
was a choice done as validation of results from another author
(n  1).
The methodological quality of the studies was moder-
ate. Overall, the median quality score was 57%, ranging from
27 to 68%. The respective median values for the clinical and
PET reports were 61% (range 34–80%) and 53% (range
5–65%).
In a first meta-analysis, we excluded the two studies
with patients without definite diagnosis of cancer.13,14 Eleven
studies were thus included in the quantitative meta-analysis.
The number of patients ranged from 38 to 162 per study, for
a total of 1108. The results are detailed in Table 3 and Figure 1.
The combined HR for the 11 studies was 2.07 (95% CI:
1.66–2.58) with a fixed-effects model, meaning that high
primary tumor SUV was associated with reduced survival.
We observed a significant heterogeneity (p  0.05) essen-
tially because of one study.23 After exclusion of that publi-
cation, the test was no more statistically significant (p 
0.31). We performed the same analysis using a random-
effects model. The HR was 2.13 (95% CI 1.54–2.95). If the
two studies13,14 including patients without histologically
proven diagnosis of lung cancer were included in the analy-
sis, we obtained an overall HR of 2.22 (95% CI 1.83–2.70)
(fixed effects) or 2.27 (95% CI 1.70–3.02) (random effects,
test for heterogeneity p  0.06).
We performed the same analysis excluding the studies
proposing a so-called best cutoff. From the eight such studies,
two were nevertheless included in the analysis because we
were able to use median SUV values instead of the value
proposed by the authors.16,20 The test for heterogeneity was
statistically significant (p  0.05). Using a random-effects
model, the combined HR was 1.77 (95% CI 1.01–3.12)
TABLE 1. Principal Characteristics of the 13 Studies Included in the Meta-Analysis
Study Publication Date n Pts ISS Stage Histology
High SUV as Prognostic
Factor for Survival
Ahuja et al.26 1998 155 1997 I–IV NSCLC Unfavorable
Sugawara et al.23 1999 38 1986 I–IV NSCLC Undetermined
Vansteenkiste et al.22 1999 125 1997 I–IIIB NSCLC Unfavorable
Dhital et al.20 2000 77 1986 IIIA Alla Unfavorable
Higashi et al.16 2002 57 1997 I–IIIB NSCLC Unfavorable
Jeong et al.18 2002 73 1997 I–IV NSCLC Unfavorable
Downey et al.25 2004 100 1997 IV NSCLC Unfavorable
Port et al.11 2005 64 1997? ? NSCLC Undetermined
Sasaki et al.24 2005 162 1997 I–IIIB NSCLC Unfavorable
Prevost et al.21 2006 120 1997 I–IV? NSCLC Unfavorable
Eschmann et al.19 2006 137 1997? III NSCLC Unfavorable
Borst et al.14 2005 51 ? I–III NSCLC Unfavorable
Cerfolio et al.13 2005 315 1997 I–IV NSCLC Unfavorable
n Pts, number of patients; ISS, date of International Staging System applied in the study; NSCLC, non-small cell lung cancer; SUV, standardized
uptake value.
a Only 2 small cell lung cancers and 1 carcinoid tumor among 77 patients.
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(Table 4). If the two studies without histologically proven
lung cancer13,14 were included, the combined HR were 2.13,
95% CI: 1.65–2.76 (fixed effects) or 2.08, 95% CI: 1.43–3.04
(random effects). Last, we looked at the role of SUV in
nonmetastatic lung cancer, excluding studies incorporating
stage IV diseases. Six publications were available, including
658 patients (Table 5). As the test for heterogeneity was not
significant (p  0.16), we used a fixed-effects model. The
combined HR was 2.09 (95% CI 1.54–2.83). When adding a
study without histologically proven lung cancer,14 the HR
was 2.23 (95% CI 1.69–2.95).
DISCUSSION
During the last decade, 18F-FDG-PET has become an
important tool used to stage patients with NSCLC. The
specific goal of this study was to evaluate its potential as a
prognostic marker. The current meta-analysis confirmed that
increased SUV of the primary tumor is a poor prognostic
factor in patients with NSCLC. It remains unclear, however,
if SUV is an independent prognostic feature as compared
with stage and performance status.
FIGURE 1. Graphical representation of the prognostic role
of primary tumor SUV on survival in lung cancer. HR and
95% confidence interval (CI) for survival comparison in stud-
ies evaluating primary tumor SUV in lung cancer. HR 1 im-
plied a survival benefit for reduced primary tumor SUVmax.
The square size is proportional to the number of patients
included in the study. The center of the diamond-shaped
lozenge at the bottom of the figure gives the combined HR
of the meta-analysis and its extremities the 95% CI HR 
2.27; 95% CI 1.70–3.02 (random-effect model). Total num-
ber of patients: 1474. SUV  standardized uptake value.
TABLE 2. Main SUV Characteristics Reported in the 13 Publications Assessable for Meta-Analysis
Study Type of SUV Correction of SUV SUV Threshold Definition SUV Threshold
Ahuja et al.26 SUV mean (SUR) Weight Best cut-off 10
Sugawara et al.3 SUV max Lean body mass Median 8.7
Vansteenkiste et al.22 SUV max Weight Best cut-off 7
Dhital et al.20 SUV max Weight Best cut-off 15 or 20
Higashi et al.16 SUV mean Weight Best cut-off 5
Jeong et al.18 SUV max Weight Best cut-off 7
Downey et al.25 SUV max Weight Median 9
Port et al.11 Unspecified SUV — Arbitrary 2.5
Sasaki et al.24 SUV max Weight Best cut-off 5
Prevost et al.21 SUV mean SUV max Weight Lean body mass Literature value 10
Eschmann et al.19 SUV mean Weight Best cut-off 12
Borst et al.14 SUV max Weight Best cut-off 15
Cerfolio et al.13 SUV max Weight Median 10
Best cut-off, author maximized the logrank test statistic to determine the best cut-off; SUV, standardized uptake value; SUR, standardized uptake
ratio.
TABLE 3. Meta-Analysis of Primary Tumor SUV Prognostic
Impact on Survival in Lung Cancer (all Studies)
References Publication Date n Pts HR 95% CI
Ahuja et al.26 1998 155 2.05 1.24–3.37
Dhital et al.20 2000 77 1.30 0.70–2.60
Downey et al.25 2004 100 2.60 1.02–6.64
Eschmann et al.19 2006 137 1.71 1.00–2.93
Higashi et al.16 2002 57 6.20 1.34–28.75
Jeong et al.18 2002 73 4.33 1.80–10.45
Port et al.11 2005 64 2.36 0.24–22.88
Prevost et al.21 2005 120 2.36 1.34–4.15
Sasaki et al.24 2005 162 7.66 1.41–41.50
Sugawara et al.23 1999 38 0.56 0.21–1.44
Vansteenkiste et al.22 1999 125 2.72 1.50–4.94
Borst et al.14 2005 51 3.15 1.59–6.22
Cerfolio et al.13 2005 315 2.65 1.63–4.31
Meta-analysis including only pathologically proven lung cancer
(n  11 studies)
Fixed effects 1108 2.07 1.66–2.58
Random effects 1108 2.13 1.54–2.95
Meta-analysis including patients without pathologically proven lung
cancer (n  13 studies)
Fixed effects 1474 2.22 1.83–2.70
Random effects 1474 2.27 1.70–3.02
HR, hazard ratio; CI, confidence interval; SUV, standardized uptake value; n Pts,
number of patients.
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Overall, the prognosis of patients with NSCLC is poor,
with less than 15% surviving beyond 5 years.4 Stage, cur-
rently determined by the 1997 International Staging System
classification, is the most important prognostic factor in
NSCLC patients having direct implications in the choice of
therapeutic options. As pointed by different authors,27,28 this
staging system still needs to be improved. The IASLC devel-
oped a task force to propose revisions for the 7th edition of
the TNM Classification of Malignant Tumors concerning lung
cancer. In this setting, a working group is assessing the
potential usefulness of new prognostic factors.
Recently, attention has focused on new biologic factors,
and the methodological group of the European Lung Cancer
Working Party and others have evaluated the most relevant
variables and found that some features could be of interest.8,29–36
Unfortunately, there are currently no data to support that any of
these markers, including genomic profiles, can accurately pre-
dict outcomes in NSCLC. The observed HR in these studies was
usually smaller in magnitude than those found in the present
meta-analysis for primary tumor SUV.
SUV is a semiquantitative index that characterizes the
tracer uptake, hence approximating the glucose metabolic
rate (Appendix 1). However, SUV estimates suffer from poor
reproducibility between centers because of the lack of stan-
dardization of the acquisition and processing protocols lead-
ing to its assessment (Appendix 2). In our study, this poor
reproducibility was evidenced by the broad range of threshold
values that have been used in the literature to distinguish
between patients with low and high survival (thresholds
varying from 2.5 to 20). Despite this variability, we were able
to show that SUV was correlated with patient survival.
Indeed, our study design calculated an HR for each study
center, based on the SUV threshold used in that study, which
somehow cancelled the threshold factor. By doing so, we
could demonstrate that SUV was certainly worth considering
as a prognostic factor, especially as, unlike immunohisto-
chemistry, it can be estimated even when no surgical speci-
men is present.
To be a practical prognostic factor in routine practice, a
single SUV threshold allowing distinguishing between long
and short survival patients should be agreed on, or the
methodology to be used to determine the optimal threshold
for each center should be established. To set a consistent
threshold, most sources of variability impacting the SUV
estimates (Appendix 2) should be removed or at least con-
trolled, for example, by phantom calibration.37 Reducing the
large variability currently affecting SUV estimates would
probably enhance the prognostic value of SUV. In our meta-
analysis, we could not take into account the variable condi-
tions in which the SUV were obtained given the poor quality
scores of the PET reports. A meta-analysis considering the
individual patient data (IPD) will be needed to try to com-
pensate for the large heterogeneity of the reported SUV.
Some biases might have occurred in our analysis.
Indeed, some studies were not included in our meta-analysis
because, e.g., separate data for lung cancer patients were not
available. We did not look at trials presented only on their
abstract form or at unpublished studies. Thus, some studies
might have not been taken into account. We limited this
problem by discussing with experts in the field during regular
meetings of the IASLC International Staging Committee. We
carefully looked at the possibility of patients’ duplication by
reporting the same cohorts in different publications. This led
us to suppress two articles,15,17 although no reference to such
duplicates was reported by the authors. Some difficulties
could happen when analyzing and comparing the results of
the individual trials. The stage and treatment case mix were
somewhat different through the studies; in particular few
treatment results were reported by the authors.
To avoid some biases of a literature-based meta-anal-
ysis, we aim to confirm our results in a meta-analysis of IPD.
Literature-based meta-analyses has the advantage of includ-
ing published trials immediately available for analysis and
which results can be checked by everyone. Although we
found in previous publications similar results with literature-
based as with IPD meta-analyses,38,39 IPD add some interest
like incorporating unpublished trials, updating results (allow-
ing to have longer survival follow-up), and particularly al-
lowing for multivariate analyses, adjusting for other vari-
ables, and subgroup analyses.
In conclusion, metabolic activity of primary tumor,
reflected by SUV measurement with 18F-FDG-PET scan is a
prognostic factor in patients with NSCLC. It still needs to be
TABLE 4. Meta-Analysis of Primary Tumor SUV Prognostic
Impact on Survival in Lung Cancer (Excluding Studies
Proposing a So-Called Best Cutoff)
References Publication Date n Pts HR 95% CI
Port et al.11 2005 64 2.36 0.24–22.88
Dhital et al.20 2000 77 1.30 0.70–2.60
Downey et al.25 2004 100 2.60 1.02–6.64
Higashi et al.16 2002 57 6.20 1.34–28.75
Prevost et al.21 2005 120 2.36 1.34–4.15
Sugawara et al.23 1999 38 0.56 0.21–1.44
Fixed effects 456 1.74 1.23–2.44
Random effects 456 1.77 1.01–3.12
HR, hazard ratio; CI, confidence interval; SUV, standardized uptake value; n Pts,
number of patients.
TABLE 5. Meta-Analysis of Primary Tumor SUV Prognostic
Impact on Survival in Lung Cancer (Excluding Studies with
Stage IV Diseases)
References Publication Date n Pts HR 95% CI
Dhital et al.20 2000 77 1.30 0.70–2.60
Eschmann et al.19 2006 137 1.71 1.00–2.93
Higashi et al.16 2002 57 6.20 1.34–28.75
Sasaki et al.24 2005 162 7.66 1.41–41.51
Vansteenkiste et al.22 1999 125 2.72 1.50–4.94
Downey et al.25 2004 100 2.60 1.02–6.64
Fixed effects 658 2.09 1.54–2.83
Random effects 658 2.27 1.45–3.54
HR, hazard ratio; CI, confidence interval; SUV, standardized uptake value; n Pts,
number of patients.
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compared with stage and performance status in a formal
analysis to determine if this adds prognostic value. We are
currently planning a meta-analysis based on IPD that will
allow multivariate analysis and potentially reduce biases
related to literature-based meta-analyses. These results may
be of particular importance in the view of the forthcoming,
7th edition of the TNM Classification for Lung Cancer.
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APPENDIX 1: DEFINITIONS OF SUVMAX AND
SUVMEAN
The standardized uptake value (SUV) is usually defined
as the tracer uptake in the tumor divided by the injected dose
normalized by the patient weight:
Suv  Tumor Uptake (kBq/mL)/
injected Dose (kBq)/Patient Weight (g) (1)
Assuming the patient has a density of 1 (1 ml  1 g),
the SUV is a dimension less index. If the tracer was uni-
formly distributed throughout the body, the SUV would be 1
in any organ. As tumors usually have an enhanced metabolic
rate, most tumors show an elevated SUV in 18F-FDG PET
(SUV 1). However, SUV is only an approximate indicator
of the glucose metabolic rate, and is by no mean an accurate
measurement of this rate.40
Although SUV is a widely accepted index for assessing
tumor uptake in 18F-FDG PET, there is no consensus regard-
ing how to estimate it. The major differences between the
estimation methods come from the way tumor uptake is
measured.41 Two classic measurement methods are:
Considering the tumor uptake is given by the maximum pixel
value in the tumor, which yields SUVmax:
Suvmax  Max Pixel Value In The Tumor (kBq/mL)/
injected Dose (kBq)/Patient Weight (g) (2)
Measuring the tumor uptake as the mean pixel value in
a volume of interest (VOI) around the tumor, which yields
SUVmean.
SuvmaxMean Pixel Value In A Tumor Voi (kBq/mL)/
injected Dose (kBq)/Patient Weight (g) (3)
Unlike SUVmax, SUVmean depends on the way the VOI
around the tumor is drawn. To avoid manual drawing that
makes the result dependent on the operator, an isocontour,
defined as a percentage of the maximum pixel value in
the tumor (typically between 50 and 80%) is often used.
However, there is no consensus on the percentage that should
be used, so even the way SUVmean is calculated can greatly
vary among centers. In addition, there are some other ways to
define the VOI, such as using a fixed sized region regardless
of the tumor size.
APPENDIX 2: FACTORS INFLUENCING THE
RESULTS OF THE SUV CALCULATION
The most important sources of variability in SUV
estimates are listed below:
Y The method of tumor uptake estimate (Appendix 1): it
greatly impacts the SUV, which can vary by a factor of
about 2 depending on the VOI considered to measure the
tumor uptake.41–43
Y The spatial resolution in the reconstructed images (de-
pending itself on the image reconstruction algorithm and
of its parameters), which directly affects the blurring of
the tumor in the images, hence the tumor pixel values.
The same tumor n with two PET imaging systems with
different spatial resolutions will appear to have different
uptakes through the partial volume effect.41,42 This is
especially true for SUVmax, which can vary by more
than 10% depending on the spatial resolution in the
reconstructed images.
Y The way the PET images have been compensated for
physical biases such as attenuation. For instance, CT-
based attenuation correction tends to yield higher SUV
(from 10 to 50%) than attenuation correction based on a
conventional PET transmission device.
Y The normalization factor used to estimate the FDG made
available to the tumor (denominator of Eq. 1). Most
often, the injected activity is normalized by the patient
weight (Eq. 1), but other normalizations, such as using
the lean body mass or the body surface area44 have been
proposed to account for the fact that body fat does not
have the same FDG uptake as lean tissues.
Y The plasma glucose level of the patient, as the FDG
competes with the plasma glucose: lower SUV are
observed in fed patients compared with patients under
fasting conditions.45 Normalization to account for the
plasma glucose level has been proposed.
Y The delay between the injection time and the imaging
time: the longer this delay, the higher the SUV, as
equilibrium is usually not reached at 45 to 60 minutes
postinjection.46 Changes in SUV between 45 minutes
and 90 minutes postinjection scans can be of about
20%.
As new corrections become available, SUV will also
depend on:
Y Whether the PET images are compensated for respira-
tory motion, e.g., using respiratory gating, as respiratory
motion introduces blur in the images, hence contributes
to lowering the pixel values in the tumor.
Y Whether the PET images are compensated for partial
volume effects.
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